Jean M. Franchi Sells 2,000 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi sold 2,000 shares of Disc Medicine stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $52.26, for a total value of $104,520.00. Following the completion of the transaction, the chief financial officer now owns 67,530 shares of the company’s stock, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $50.09 on Friday. The stock has a market cap of $1.73 billion, a P/E ratio of -12.78 and a beta of 0.73. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The stock has a 50 day moving average of $46.96 and a two-hundred day moving average of $52.97. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). On average, research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in IRON. Sterling Capital Management LLC increased its position in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $40,000. Amalgamated Bank raised its stake in shares of Disc Medicine by 38.6% during the first quarter. Amalgamated Bank now owns 787 shares of the company’s stock worth $39,000 after purchasing an additional 219 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Disc Medicine by 13,428.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company’s stock worth $47,000 after purchasing an additional 940 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on IRON. Cantor Fitzgerald increased their target price on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Disc Medicine in a report on Monday. Scotiabank raised their target price on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. TD Cowen started coverage on Disc Medicine in a research note on Thursday, February 27th. They set a “buy” rating for the company. Finally, Raymond James Financial assumed coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They issued a “strong-buy” rating and a $89.00 price target on the stock. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $96.70.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.